Key opinion leaders in the treatment of myeloproliferative neoplasms, Pankit Vachhani, MD, and Jamile Shammo, MD, share expert perspectives on ruxolitinib for patients with primary myelofibrosis and polycythemia vera.
EP. 1: Myeloproliferative Neoplasms: Diagnosing Polycythemia Vera
An expert in hematologic malignancies, Jamile Shammo, MD, FASCP, FACP, provides an overview of the 2016 WHO diagnostic criteria for polycythemia vera and considers the role of genetic testing.
EP. 2: Risk Stratification and Treatment Considerations in PV
A key opinion leader in the management of polycythemia vera discusses risk stratification and reflects on factors that influence the decision to observe or treat the patient’s disease.
EP. 3: PV Treatment Options and Dosing
Jamile Shammo, MD, FASCP, FACP, shares insight into the currently available treatment options for polycythemia vera and examines how treatment intolerance and/or resistance can impact the therapeutic approach.
EP. 4: The JAK2 Pathway in Polycythemia Vera
A specialist in hematologic malignancies provides an overview of the JAK2 pathway as it relates to myeloproliferative neoplasms such as polycythemia vera.
EP. 5: Ruxolitinib in PV: The RESPONSE Trial
Renowned expert in the management of MPNs, Jamile Shammo, MD, FASCP, FACP, reviews the RESPONSE trial of ruxolitinib in patients with PV and discusses the agent’s safety and efficacy.
EP. 6: Ruxolitinib in PV: The RESPONSE-2 Trial
Jamile Shammo, MD, FASCP, FACP, continues her discussion of ruxolitinib for polycythemia vera by examining the results of the RESPONSE-2 trial and sharing personal experience managing toxicity in clinic.
EP. 7: Future Directions in the Treatment of Polycythemia Vera
A thought leader in hematologic malignancies provides key insights into the future of treatment for polycythemia vera by considering the potential role of treatment sequencing or combination therapy.
EP. 8: Risk Stratification: Primary Myelofibrosis
An overview of risk stratification models available to assess and classify patients with primary myelofibrosis.
EP. 9: Treatment Approaches for Myelofibrosis
Pankit Vachhani, MD, comments on goals of therapy for patients with myelofibrosis and highlights traditional treatment approaches.
EP. 10: Myelofibrosis: Treatment Planning and Management
Criteria and assessments that can be used to help clinicians select treatment and monitor patients on therapy for myelofibrosis.
EP. 11: Ruxolitinib for Myelofibrosis: Treatment Considerations
Pankit Vachhani, MD, explains how to properly treat myelofibrosis using ruxolitinib based on data provided by key clinical trials like COMFORT-I and COMFORT-II.
EP. 12: Selecting Therapy to Treat Myelofibrosis
Patient factors and disease characteristics that impact decisions to treat patients with myelofibrosis with ruxolitinib or fedratinib.
EP. 13: Unmet Needs in Management of Myeloproliferative Neoplasms
Pankit Vachhani, MD, reacts to treatment limitations for health care professionals who care for patients with myeloproliferative neoplasms.
Dr. Krop on Trastuzumab Deruxtecan in HER2+ Metastatic Breast Cancer
Breast Cancer Index Risk Scores Are Prognostic for Premenopausal Women With HR+ Breast Cancer Receiving Adjuvant Endocrine Therapy
Black Women With HR+ Breast Cancer Have Worse Outcomes, Despite Similar Recurrence Scores
Benefit of Adjuvant Abemaciclib Increases at 4-Year monarchE Landmark Analysis for Patients With HR+/HER2– High-Risk Early Breast Cancer
2 Clarke DriveSuite 100Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.